Clinical trial · Interventional
Exercise for the Treatment of Cancer-Related Sarcopenia
Exercise for the Treatment of Cancer-Related Sarcopenia: a Randomised Controlled Trial.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our primary objective is to assess the effects of exercise on cancer-related sarcopenia and its hallmarks, including muscle strength, muscle mass, and physical performance. The secondary objectives are to examine exercise adherence and the effects of exercise on health-related quality of life (QoL), cancer-related fatigue, and sleep quality. Additionally, we will explore the effects of exercise on bone and fat mass as secondary outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Multimodal, supervised exercise training | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Exercise intervention group
- description
- The exercise group will be asked to complete 48 multicomponent, supervised exercise training sessions over 24 weeks, with a frequency of two sessions per week on non-consecutive days.
- interventionNames
- Other: Multimodal, supervised exercise training
- type
- NO_INTERVENTION
- label
- Control group
- description
- Patients in the waiting list control group received standard medical care without any exercise program or specific exercise recommendations. To maintain contact with the researchers and minimize drop-out, the waiting list control group received general health information through monthly online meetings.
Primary outcomes (1)
- measure
- sarcopenia
- timeFrame
- baseline, week 24 (post exercise)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years old women with a confirmed diagnosis of breast or gynecological cancer. * Any level of sarcopenia (pre-sarcopenia, sarcopenia, or severe sarcopenia). * Patients must have completed their primary treatment regimen (surgery, chemotherapy, and/or radiotherapy) for at least 2 weeks and up to 2 years before enrolment. * have received the medical consent to be engaged in physical exercise programs. Exclusion Criteria: * The presence of one or more comorbidities that could potentially interfere with attendance or test results (e.g., other cancers or acute or chronic renal failure); * Already in exercise programs comparable to the HERA program; * Evidence of severe cardiovascular disease as a result of an electrocardiogram.
References
Publications (0)
Data not yet available